Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A phase I, pharmacokinetic, and biological correlative study - Ricart, A D; Tolcher, A W; Liu, G (Clin Cancer Res, 2008)
et al.